4.7 Review

IL-17 and IL-17-producing cells in protection versus pathology

Journal

NATURE REVIEWS IMMUNOLOGY
Volume 23, Issue 1, Pages 38-54

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41577-022-00746-9

Keywords

-

Categories

Ask authors/readers for more resources

IL-17 cytokines have both protective and pathological functions in the context of infection and autoimmunity. They promote protective immunity against pathogens but can also drive inflammatory pathology. Dysregulated IL-17 responses can contribute to immunopathology, and IL-17 is implicated in various inflammatory diseases.
IL-17 cytokines drive biological responses that protect the host against many infections but can also contribute to host pathology in the context of infection and autoimmunity. Here, Kingston Mills highlights the different cellular sources of IL-17 and compares the pathological versus protective functions of these cytokines. IL-17 cytokine family members have diverse biological functions, promoting protective immunity against many pathogens but also driving inflammatory pathology during infection and autoimmunity. IL-17A and IL-17F are produced by CD4(+) and CD8(+) T cells, gamma delta T cells, and various innate immune cell populations in response to IL-1 beta and IL-23, and they mediate protective immunity against fungi and bacteria by promoting neutrophil recruitment, antimicrobial peptide production and enhanced barrier function. IL-17-driven inflammation is normally controlled by regulatory T cells and the anti-inflammatory cytokines IL-10, TGF beta and IL-35. However, if dysregulated, IL-17 responses can promote immunopathology in the context of infection or autoimmunity. Moreover, IL-17 has been implicated in the pathogenesis of many other disorders with an inflammatory basis, including cardiovascular and neurological diseases. Consequently, the IL-17 pathway is now a key drug target in many autoimmune and chronic inflammatory disorders; therapeutic monoclonal antibodies targeting IL-17A, both IL-17A and IL-17F, the IL-17 receptor, or IL-23 are highly effective in some of these diseases. However, new approaches are needed to specifically regulate IL-17-mediated immunopathology in chronic inflammation and autoimmunity without compromising protective immunity to infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available